nChroma Bio
nChroma Bio is a genetic medicines company developing programmable in vivo delivery technologies combined with gene-regulating cargos to create targeted, durable therapies. The company focuses on liver-directed and extrahepatic delivery approaches and is advancing an epigenetic editing lead candidate for chronic hepatitis B through preclinical and CTA-enabling studies.
Industries
Nr. of Employees
small (1-50)
nChroma Bio
Patents
CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome
US-12331328-B2
View Details
CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome
US-12331328-B2
View DetailsProducts
CRMA-1001
A liver-directed epigenetic editor delivered via lipid nanoparticles designed to durably silence hepatitis B virus (targeting cccDNA and integrated HBV DNA) using methylation-based epigenetic modulation without DNA cutting.
CRMA-1001
A liver-directed epigenetic editor delivered via lipid nanoparticles designed to durably silence hepatitis B virus (targeting cccDNA and integrated HBV DNA) using methylation-based epigenetic modulation without DNA cutting.
Services
Partnering to apply modular delivery solutions and genetic cargos to joint discovery and development programs.
Partnering to apply modular delivery solutions and genetic cargos to joint discovery and development programs.
Expertise Areas
- Epigenetic editing and gene regulation
- In vivo targeted delivery
- Liver-directed therapeutics
- Extrahepatic delivery using engineered particles
Key Technologies
- Lipid nanoparticles (LNPs)
- Engineered virus-like particles (eVLP/DLVR)
- Epigenetic editors (DNA methylation-based)
- Ribonucleoprotein (RNP) delivery of gene editors (base editors, prime editors, CRISPR/Cas)
News & Updates
Three abstracts accepted for ASGCT 2025 including one oral and two poster presentations on in vivo targeting of HSPCs and engineered virus-like particles.
Three abstracts accepted for The Liver Meeting® 2025 including a Poster of Distinction on preclinical pharmacology and safety of CRMA-1001.
Media coverage summarizing the company's $75M financing and merger forming nChroma Bio to advance epigenetic editing and delivery platforms.
Industry coverage of the merger combining epigenetic editing technologies with non-viral delivery approaches to form nChroma Bio.
Oversubscribed $75 million financing completed at launch to support lead program and platform advancement.
Preclinical studies reported >3 log reduction in HBsAg in mouse models with durability and supportive non-human primate surrogate data demonstrating durable PCSK9 silencing.
Three abstracts accepted for ASGCT 2025 including one oral and two poster presentations on in vivo targeting of HSPCs and engineered virus-like particles.
Three abstracts accepted for The Liver Meeting® 2025 including a Poster of Distinction on preclinical pharmacology and safety of CRMA-1001.
Media coverage summarizing the company's $75M financing and merger forming nChroma Bio to advance epigenetic editing and delivery platforms.
Industry coverage of the merger combining epigenetic editing technologies with non-viral delivery approaches to form nChroma Bio.
Oversubscribed $75 million financing completed at launch to support lead program and platform advancement.
Preclinical studies reported >3 log reduction in HBsAg in mouse models with durability and supportive non-human primate surrogate data demonstrating durable PCSK9 silencing.